BioBlog

The U.S. Department of Justice gave the green light for six pharmaceutical companies to share manufacturing data in the quest for COVID-19 therapeutics. The companies may not, however, share pricing information and production costs. And changes are happening in the world of oncology from a new

This week's Innovation Partners BioBlog contains several updates from major players in the pharmaceutical industry. Novartis' sales dropped in the second quarter after early pandemic drug stockpiling boosted Q1 sales. The company is also struggling with unanticipated and serious side effects

U.S. health officials stated they expect to have 300 million doses of a vaccine for the novel coronavirus by early 2021 despite the fact that a final vaccine candidate has not been chosen. NCCN makes the case for biosimilars to help in the fight against cancer, and Roche is set to pay $775 million

In this week’s Innovation Partners BioBlog, we take a look at several updates from companies and groups working on treatments and vaccines for the novel coronavirus. A bipartisan group seeks to protect hospitals from losing their 340B status due to lower inpatient hospital admissions from specific

Happy Independence Day to all of our American readers! In this week’s Innovation Partners BioBlog, we take a look at several updates from the pharmaceutical world. AstraZeneca is the first company to participate in a new FDA program to disclose all patient-reported symptoms during drug trials. The

Breakthroughs announced this week at the AACR Virtual Meeting show that the pace of cancer diagnosis, testing, and treatment hasn't slowed despite the worldwide pandemic. Clinical trials of a new personalized cancer vaccine show promise, while researchers appear to have developed a blood test that

This week’s Innovation Partners BioBlog focuses on oncology updates. NICE backs funding for Roche’s lung cancer drug, Rozlytrek, after the company offers discounts. New personalized oncology treatments may be available based on patients’ genetic profiles thanks to a partnership between MD Anderson

In this week’s edition of the Innovation Partners BioBlog, we look at two stories related to pharmaceutical giant AstraZeneca. AstraZeneca has identified two potential antibodies against COVID-19 and expect to move them into the clinic by August. However, this means that AstraZeneca’s merger with